The Role of Pregnane Neurosteroids in Ethanol Withdrawal: Behavioral Genetic Approaches
January 2004
in “
Pharmacology & Therapeutics
”
New to Finasteride? There is a guide in the encyclopedia. Read the guide → Studysummary This review explores the potential role of pregnane neurosteroids in modulating alcohol withdrawal symptoms, suggesting a therapeutic target for treating alcohol dependence, but reports no new clinical results.
Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
The study investigated the impact of pregnane neurosteroids, especially allopregnanolone (ALLOP), on ethanol withdrawal, emphasizing their interaction with GABAA receptors. It was observed that chronic ethanol exposure and withdrawal altered neurosteroid levels and sensitivity, with seizure-prone animals exhibiting reduced ALLOP levels and tolerance to its anticonvulsant effects. Adjusting ALLOP levels using finasteride lessened withdrawal severity. Genetic research indicated interactions between GABAA receptor subunits and the enzyme 5α-reductase, suggesting that neurosteroid biosynthesis could be a therapeutic target for alcohol dependence. The study underscored the potential of neurosteroid treatment during ethanol withdrawal and proposed that genetic variations might affect withdrawal severity.
